Canadian Pacific Kansas City Limited Common Shares vs BIO-TECHNE Corp — how do they compare? Canadian Pacific Kansas City Limited Common Shares trades at $84.46 (market cap $73.98B), while BIO-TECHNE Corp trades at $72.46 (market cap $11.36B). The key difference: Canadian Pacific Kansas City Limited Common Shares is far larger — about 6.5× BIO-TECHNE Corp's market cap, and Canadian Pacific Kansas City Limited Common Shares pays the higher dividend (0.9%). Which is the better fit depends on your goals.
| CP | TECH | |
|---|---|---|
Market Cap | $73.98B | $11.36B |
Volume | 1,669,828 | 5,390,331 |
Sector | Industrials | Health |
52-Week High | $96.69 | $72.61 |
52-Week Low | $68.88 | $43.31 |
Enterprise Value | $91.36B | $11.39B |
Dividend Yield | 0.9% | 0.44% |
Typical Hold Time | — | 64 Days |
Signals from Pluang's Aura AI — not financial advice
No Aura AI signal available yet.
TECH trades at $72.46, near its 52-week high of $72.70, with a slight daily decline of 0.1%. The stock shows a bullish technical signal from moving averages, while oscillators are neutral. Recent earnings have been mixed, with a Q2 2026 beat but a Q1 miss. The company maintains strong gross margins of 65.77%, though net income margin has compressed to 14.97% in 2025 from 24.6% in 2022. A significant development is the shareholder-approved acquisition by Merck KGaA at $73.00 per share, pending completion.
The pending acquisition at $73.00 offers a clear near-term upside of about 0.7% from the current price, limiting downside risk. However, execution risks remain until deal closure, and profitability pressures pose concerns for standalone operations. Analyst consensus is divided with 46% Buy and 54% Hold ratings, reflecting cautious optimism amid transition uncertainty.
Trailing returns across standard periods
Latest headlines on both assets
Canadian Pacific Kansas City operates a freight railway connecting Canada, the United States, and Mexico. The company was formed through the combination of Canadian Pacific and Kansas City Southern.
Read more on CP →Based in Minnesota, Bio-Techne is a life sciences manufacturer supplying consumables and instruments for the pharma, biotech, academic, and diagnostic markets. The company reports in two segments, protein sciences (75% of revenue), and diagnostics and genomics (25%). The protein-focused segment makes equipment and associated consumables for protein characterization and analysis and sells antibodies for research and clinical purposes. In diagnostics, Bio-Techne provides controls and calibrators for diagnostic manufacturers and has a portfolio of diagnostic oncology assays. The United States accounts for about 55% of revenue, and the firm also has operations in EMEA (20% of sales), the U.K. (5%), and APAC (15%), with the rest of the world accounting for the remaining 5%.
Read more on TECH →